Back to results
US 7,842,482 B2Granted
Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer
AssigneeThe Chinese University of Hong Kong
InventorsYuk Ming Dennis Lo, Kwan Chee Allen Chan
Life of this patent
Estimating the term…
Abstract
Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and/or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed.
Claims21
A method for diagnosis of an Epstein-Barr virus (EBV)-associated cancer in an individual comprising:
- (a) obtaining a urine sample from the individual;
- and
- (b) (1) extracting nucleic acids from the urine sample,
- (2) amplifying an EBV associated nucleic acid sequence using a fragment of the BamHI-W region of the EBV genome as a template, wherein the amplified EBV associated nucleic acid sequence is no more than 76 nucleotides in length, and
- (3) detecting the amplified EBV associated nucleic acid sequence,
- wherein the presence of the amplified EBV associated nucleic acid sequence indicates that the individual is suffering from an EBV-associated cancer.
3 more elements
A method for prognosis of an EBV-associated cancer in an individual comprising:
- (a) obtaining a urine sample from the individual;
- and
- (b) (1) extracting nucleic acids from the urine sample,
- (2) amplifying an EBV associated nucleic acid sequence using a fragment of the BamHI-W region of the EBV genome as a template, wherein the amplified EBV associated nucleic acid sequence is no more than 76 nucleotides in length, and
- (3) detecting the amplified EBV associated nucleic acid sequence,
- wherein the presence of the amplified EBV associated nucleic acid sequence indicates a poor prognosis of the EBV-associated cancer.
3 more elements
A method for monitoring an EBV-associated cancer in an individual comprising:
- (a) obtaining urine samples from the individual at different time points;
- and
- (b) (1) extracting nucleic acids from the urine samples,
- (2) amplifying an EBV associated nucleic acid sequence using a fragment of the BamHI-W region of the EBV genome as a template, wherein the amplified EBV associated nucleic acid sequence is no more than 76 nucleotides in length, and
- (3) detecting or quantifying the amplified EBV associated nucleic acid sequence,
- wherein the presence or an increased level of the EBV associated nucleic acid sequence in the urine samples indicates the progression of the EBV-associated cancer, and the absence or a decreased level of the EBV associated nucleic acid sequence in the urine samples indicates the regression of the EBV-associated cancer.
3 more elements
Dependencies are inferred from the claim text.